Generalized cost-effectiveness analysis of pharmaceutical interventions for primary prevention of cardiovascular disease in Thailand

Khonputsa, P., Veerman, J. L., Bertram, M. and Vos, T. (2010). Generalized cost-effectiveness analysis of pharmaceutical interventions for primary prevention of cardiovascular disease in Thailand. In: ISPOR 4th Asia-Pacific Conference Research Abstracts. ISPOR 4th Asia-Pacific Conference, Phuket, Thailand, (A520-A520). 5-7 September 2010. doi:10.1111/j.1524-4733.2010.00793_3.x


Author Khonputsa, P.
Veerman, J. L.
Bertram, M.
Vos, T.
Title of paper Generalized cost-effectiveness analysis of pharmaceutical interventions for primary prevention of cardiovascular disease in Thailand
Conference name ISPOR 4th Asia-Pacific Conference
Conference location Phuket, Thailand
Conference dates 5-7 September 2010
Proceedings title ISPOR 4th Asia-Pacific Conference Research Abstracts   Check publisher's open access policy
Journal name Value in Health   Check publisher's open access policy
Place of Publication Hoboken, NJ, U.S.A.
Publisher Wiley-Blackwell Publishing
Publication Year 2010
Sub-type Poster
DOI 10.1111/j.1524-4733.2010.00793_3.x
ISSN 1098-3015; 524-4733
Volume 13
Issue 7
Start page A520
End page A520
Total pages 1
Language eng
Formatted Abstract/Summary
Objectives: To assess cost-effectiveness of blood pressure and/or cholesterol lowering drugs for cardiovascular disease prevention.

Methods:
Design: A Markov model using Generalized Cost-Effectiveness Analysis with “do-nothing” as a comparator; health sector perspective on life time cost-effectiveness and 3% discounting for both cost and effects. Setting: Primary care, Thailand Target Population: Thai population aged 30 years or above in 2004 classified by 10-year absolute risk of cardiovascular disease. Intervention: Blood pressure and cholesterol lowering drugs. Outcome Measure: Average and incremental cost-effectiveness in Thai baht per disability adjusted life-year averted.

Results: Base-Case Analysis: The most cost-effective option or cardiovascular disease prevention in people with 10-year risks of 5% and greater was the polypill followed by combinations of three blood pressure drugs with or without a statin. Single generic drugs, except angiotensin reuptake blockers were also very cost-effective, but dominated by drug combinations due to greater health gain and shared costs. Sensitivity Analysis: All generic drugs except beta blockers and angiotensin reuptake blockers, and the above combinations were very cost-effective; the median cost effectiveness ratios for all of these drugs were below one times gross domestic product per capita in people with 10-year risks of 5% and greater.

Conclusions: Primary cardiovascular disease prevention with a combination of generic drugs in Thailand is very cost-effective when the 10-year absolute risk is 5% or higher.

Q-Index Code EX
Q-Index Status Provisional Code
Institutional Status UQ
Additional Notes Poster no.PCV20.

Document type: Conference Paper
Collection: School of Public Health Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Google Scholar Search Google Scholar
Created: Sun, 09 Jan 2011, 00:00:18 EST